A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q36928318

about

The blind men and the AML elephant: can we feel the progress?Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia Update on rational targeted therapy in AML Antibody-drug conjugates--an emerging class of cancer treatment Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances An update of current treatments for adult acute myeloid leukemia Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Pediatric AML: From Biology to Clinical Management Volasertib for AML: clinical use and patient consideration Progress in acute myeloid leukemia Theranostic applications of antibodies in oncology.CD133, Selectively Targeting the Root of Cancer Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities 'Acute myeloid leukemia: a comprehensive review and 2016 update'Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.The Globalization of Cooperative Groups.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.Is targeted therapy feasible in acute myelogenous leukemia?G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.Immunotherapy for pediatric leukemia.

P2860

Q26749614-6326C2FA-F115-48FC-8613-25F2F1F523FC Q26765858-443E7E68-0632-4DB2-9B81-4E8A7B164F10 Q26766152-EEA93B96-2A42-434A-A04F-18A6117BA0FD Q26770312-9BA529A7-5651-4C92-8459-57115DB35C96 Q26775720-B48D9549-6F7E-4573-B9F4-1E75C29A7B24 Q26776396-270B43BE-9E9F-47CC-A8B1-2B0C766E8F5C Q26799609-745EEC0C-C809-4104-964B-A5E8B141DFB8 Q26799773-58213DC0-FBA7-44AD-A2FF-9CB13B9C7F13 Q26801131-61272C57-B2C7-42ED-A4B4-949C8013825B Q27024006-8DC2CA68-4207-431A-98B5-6AC18459298A Q27693293-B60B2FF3-7182-4E46-8471-6807A85D9D7A Q28066353-6F4A7CB6-83D3-47F4-AFC8-F50A6E26E6B1 Q28071384-A514226E-FC50-41C5-A98C-E5CB3BB838E7 Q28072539-6220F52A-7AD2-4FE7-A148-C9FD69F78B96 Q30249246-0EDF179C-A77A-4D0B-BC67-AA15F38CF531 Q30835785-859DBAF1-3812-4E12-B8E2-76A37E5934F4 Q33437992-4665F450-082A-4CE2-9796-FB9A24CF2D08 Q33643108-3CC1E0BF-6C9B-49EB-B768-4C530607509B Q33829283-BBA8909D-210B-4631-9061-4006408D2C6C Q33903030-B0BAC9C3-3A6F-443C-BD2B-44012025AD2A Q34172042-DE25DB61-9B41-4EBA-9EB3-E743447B50D0 Q34318490-AC73122A-7987-4767-9A86-E8B253B563A9 Q34655256-D6012B13-0D85-46E9-81F6-444779DE16C3 Q35146288-87102026-7165-4411-A8DD-6443EEFCC022 Q35215042-ADE1652C-AC74-4FE0-869A-A07A1FAE56C3 Q35285004-115CDD16-DDFE-472A-BCEB-448B6FD151F2 Q35606252-38B4E88D-589D-4FDB-B704-2171CA6AA0F4 Q35845907-73BE0B37-DDAE-4143-90DB-C9E524BDB4FA Q35987611-F3D05628-06FD-4EC8-8238-BB3451629105 Q36119749-F72E6B34-44D2-45C4-9F88-0081DEAB06AD Q36273796-12BC6FFE-4C1A-41ED-8BA4-F3EC2E91AAE2 Q36344469-08FAB1A4-67A0-4872-BCE3-5CCCAB7E4F02 Q36416358-B985CBA9-B18B-4016-83E0-462B073BC2A7 Q36478979-2EDA941A-5C30-4382-AE91-CD6854A8D608 Q36568466-B29BE299-07E0-4484-8B64-86101C0036FE Q36655704-86F499C7-8DED-4CA9-9AE4-CC80FC98B590 Q36682845-6B16286D-3286-4711-A5BA-4CBCF04C0FCB Q36805474-839BC042-5071-4A49-88A4-ABEF44E0D1E8 Q36914445-36784867-C070-4EB2-9F72-59EBB5A4DC81 Q36968163-6F305DA2-E76E-420A-8067-7E362A231F67

P2860

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q36928318

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

A phase 3 study of gemtuzumab ...... s with acute myeloid leukemia.

@en

type

label

A phase 3 study of gemtuzumab ...... s with acute myeloid leukemia.

@en

prefLabel

A phase 3 study of gemtuzumab ...... s with acute myeloid leukemia.

@en

P1433

Q36928318-19E329B7-75CC-42E0-A6E2-741F935F814F

P1476

Q36928318-475F1321-5755-4A2F-8D9B-14731BED8E69

P2093

Q36928318-0F62B464-E70B-4A56-8630-778CBF33CBC2

Q36928318-1854AFC1-0083-4EF4-89E0-AAAF6D363A80

Q36928318-1D44A61D-3BB4-421F-BBE2-7A44FDE7AB8B

Q36928318-34CBF8F6-D67B-48A5-A49B-03A0B5BCEEAB

Q36928318-3C5AE3C9-BB75-4410-A776-B45A85373CE2

Q36928318-5B4F9A15-20A8-4166-8B5B-9C0CE40E1354

Q36928318-82C89410-26AD-4221-A3FB-7970951746B4

Q36928318-AABA60B6-3C9B-4749-988E-94DA58A4E22D

Q36928318-F6E075E0-D2EF-483B-9668-3CE6AE693C05

Q36928318-FEA97B31-695D-4F6E-B510-8216E450524C

P2860

Q36928318-26C9E3A6-FBD5-4A7E-9830-866F797AA660

Q36928318-345F06F2-299C-414D-B416-A90A43892AB6

Q36928318-3841D452-A0D6-4B6E-A5F3-1B4757BFE656

Q36928318-5C0234BA-9D5B-4011-B935-43EE7BC081EB

Q36928318-5F880611-E5EA-47D0-A930-F0DA212A106F

Q36928318-69740817-FC1F-463E-B4EE-37CB2660C26A

Q36928318-769B19E9-7D38-4744-B5D9-D45AB962A7D3

Q36928318-8903CA2A-F25D-4FE1-812B-C909B7A448BD

Q36928318-B8A42AA2-DE9E-4E35-BD03-E343FCE3CF24

Q36928318-BD4649E1-26AC-47E7-863F-3ACA4CE7197D

P304

Q36928318-D12D98C8-A684-4009-BDF4-51A06AD0E38E

P31

Q36928318-343F12CD-7BA8-4D69-9DDB-BD070DDBFC62

P356

Q36928318-4E351AA5-0027-45F6-8CA3-507877284523

P407

Q36928318-89CED316-A8FD-434E-8D32-C0F0A59551C8

P433

Q36928318-10B30DF0-6FE9-4FFB-AC6B-674F806FA213

P478

Q36928318-8C3263AB-9BD8-497D-BC22-7D3D1FC211A0

P50

Q36928318-5713A9DB-2A42-41A7-89A2-65C42949704D

Q36928318-5D3B686D-1748-4E9F-8D99-23DFA9B2769E

Q36928318-64079191-A083-46A5-AC2E-5B96E8220E2F

Q36928318-CA0DCBCA-9805-439D-876A-F79E4436EF80

P577

Q36928318-55ABED76-0A85-4FD1-87F3-27D502FAA152

P5875

Q36928318-B1B98450-B17B-4919-B2B2-96AED0A50DF8

P698

Q36928318-66E60084-9992-4D04-85EB-91020A428F6C

P921

Q36928318-CC19133B-B31D-4296-AD49-C54CF92B0038

P932

Q36928318-F7D6C6E4-0533-4016-8D83-6D63909AEADA

P356

BLOOD-2013-01-466706

P1433

P1476

A phase 3 study of gemtuzumab ...... s with acute myeloid leukemia.

@en

P2093

Cheryl Willman

http://www.w3.org/2001/XMLSchema#string

Harry P Erba

http://www.w3.org/2001/XMLSchema#string

Joseph Brandwein

http://www.w3.org/2001/XMLSchema#string

Kenneth J Kopecky

http://www.w3.org/2001/XMLSchema#string

Leif Stenke

http://www.w3.org/2001/XMLSchema#string

Marilyn Slovak

http://www.w3.org/2001/XMLSchema#string

Patrick J Stiff

http://www.w3.org/2001/XMLSchema#string

Richard A Larson

http://www.w3.org/2001/XMLSchema#string

Roland B Walter

http://www.w3.org/2001/XMLSchema#string

Thomas Nevill

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Gemtuzumab ozogamicin: time to resurrect?

Anthracycline dose intensification in acute myeloid leukemia.

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.

Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century.

P304

4854-4860

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-01-466706

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Martin S Tallman

Frederick R. Appelbaum

Stephen H Petersdorf

P577

2013-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236206232

http://www.w3.org/2001/XMLSchema#string

P698

23591789

http://www.w3.org/2001/XMLSchema#string

P921

P932

3682338

http://www.w3.org/2001/XMLSchema#string